Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. |